Literature DB >> 9516026

European network for the case-population surveillance of rare diseases (Euronet). A prospective feasibility study.

D Capellà1, J R Laporte, X Vidal, B E Wiholm, B Bégaud, M J Langman, M Rawlings.   

Abstract

OBJECTIVE: Euronet, a case-population surveillance scheme, aims to estimate the risk of certain rare conditions which are commonly iatrogenic, by comparing drug use amongst non-selective cases with overall drug use in the general population.
METHODS: The method is based on three provisos: (1) all incident cases (irrespective of suspected aetiology) should be ascertained and studied; (2) a full drug history should be obtained from cases by direct interview; and (3) drug-use data for the products of interest should be available for this population from which cases are chosen. The feasibility of this problem-oriented approach for the identification of new signals of adverse drug reactions and for risk estimation will be tested in relation to agranulocytosis, Stevens-Johnson syndrome and toxic epidermal necrolysis in four defined areas in Europe, totalling 19 x 10(6) inhabitants, with these latest two outcomes being studied in only three regions. The design, methods and main limitations of this case-population surveillance approach are described.

Entities:  

Mesh:

Year:  1998        PMID: 9516026     DOI: 10.1007/s002280050382

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  8 in total

Review 1.  Case-population studies in pharmacoepidemiology.

Authors:  Dolors Capellà; Consuelo Pedrós; Xavier Vidal; Joan-Ramon Laporte
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

2.  The case-population study design: an analysis of its application in pharmacovigilance.

Authors:  Hélène Théophile; Joan-Ramon Laporte; Nicholas Moore; Karin-Latry Martin; Bernard Bégaud
Journal:  Drug Saf       Date:  2011-10-01       Impact factor: 5.606

3.  Vaccine Case-Population: A New Method for Vaccine Safety Surveillance.

Authors:  Hélène Théophile; Nicholas Moore; Philip Robinson; Bernard Bégaud; Antoine Pariente
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

Review 4.  The role of the clinical pharmacologist in the management of adverse drug reactions.

Authors:  N Moore
Journal:  Drug Saf       Date:  2001-01       Impact factor: 5.606

5.  Agranulocytosis associated with dipyrone (metamizol).

Authors:  Luisa Ibáñez; Xavier Vidal; Elena Ballarín; Joan-Ramon Laporte
Journal:  Eur J Clin Pharmacol       Date:  2004-12-03       Impact factor: 2.953

6.  Incidence of agranulocytosis in Southwest France.

Authors:  Hélène Théophile; Bernard Bégaud; Karin Martin; Juan Ramon Laporte; Dolores Capella
Journal:  Eur J Epidemiol       Date:  2004       Impact factor: 8.082

7.  Evaluation of the extent of under-reporting of serious adverse drug reactions: the case of toxic epidermal necrolysis.

Authors:  Nicole Mittmann; Sandra R Knowles; Manuel Gomez; Joel S Fish; Robert Cartotto; Neil H Shear
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

8.  The past, present and perhaps future of pharmacovigilance: homage to Folke Sjoqvist.

Authors:  Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2013-05-03       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.